Cargando…

Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy

BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Weisheng, Xue, Wangsheng, Zhou, Zeyu, Wang, Jiying, Qi, Hui, Sun, Shiyu, Jin, Tong, Yao, Ping, Zhao, Jian-Yuan, Lin, Fuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576463/
https://www.ncbi.nlm.nih.gov/pubmed/37842336
http://dx.doi.org/10.2147/DMSO.S428933
_version_ 1785121127296663552
author Xu, Weisheng
Xue, Wangsheng
Zhou, Zeyu
Wang, Jiying
Qi, Hui
Sun, Shiyu
Jin, Tong
Yao, Ping
Zhao, Jian-Yuan
Lin, Fuqing
author_facet Xu, Weisheng
Xue, Wangsheng
Zhou, Zeyu
Wang, Jiying
Qi, Hui
Sun, Shiyu
Jin, Tong
Yao, Ping
Zhao, Jian-Yuan
Lin, Fuqing
author_sort Xu, Weisheng
collection PubMed
description BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been identified in the clinic so far. This study is to investigate the potential serum biomarkers for DPN firstly based on (1)H-Nuclear Magnetic Resonance ((1)H-NMR)-based metabolomics technique. METHODS: Thirty-six patients enrolled in this study were divided into two groups: 18 T2DM patients without DPN (T2DM group) and 18 T2DM patients with DPN (DPN group). Serum metabolites were measured via (1)H-NMR spectroscopy. Bioinformatic approaches including principal component analysis (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA), independent sample t-test, Fisher’s test, Pearson and Spearman correlation analysis, Stepwise multiple linear regression analysis and receiver operating characteristic (ROC) curve analysis were used to identify the potential altered serum biomarkers. RESULTS: A total of 20 metabolites were obtained and further analyzed. Formate was identified as the only potential biomarker that decreased in the DPN group with statistical significance after multiple comparisons (p<0.05). Formate also displayed a negative relationship with some elevated clinical markers in DPN. ROC curve analysis showed a good discriminative ability for formate in DPN with an area under the curve (AUC) value of 0.981. CONCLUSION: Formate could be considered a potential serum metabolic biomarker for DPN. The reduced level of formate in DPN may be associated with mitochondrial dysfunction and gut microbiota alteration. Monitoring the level of serum formate would be an important strategy for the early diagnosis of DPN and a supplement of formate may be a promising treatment for DPN in the future.
format Online
Article
Text
id pubmed-10576463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105764632023-10-15 Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy Xu, Weisheng Xue, Wangsheng Zhou, Zeyu Wang, Jiying Qi, Hui Sun, Shiyu Jin, Tong Yao, Ping Zhao, Jian-Yuan Lin, Fuqing Diabetes Metab Syndr Obes Original Research BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been identified in the clinic so far. This study is to investigate the potential serum biomarkers for DPN firstly based on (1)H-Nuclear Magnetic Resonance ((1)H-NMR)-based metabolomics technique. METHODS: Thirty-six patients enrolled in this study were divided into two groups: 18 T2DM patients without DPN (T2DM group) and 18 T2DM patients with DPN (DPN group). Serum metabolites were measured via (1)H-NMR spectroscopy. Bioinformatic approaches including principal component analysis (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA), independent sample t-test, Fisher’s test, Pearson and Spearman correlation analysis, Stepwise multiple linear regression analysis and receiver operating characteristic (ROC) curve analysis were used to identify the potential altered serum biomarkers. RESULTS: A total of 20 metabolites were obtained and further analyzed. Formate was identified as the only potential biomarker that decreased in the DPN group with statistical significance after multiple comparisons (p<0.05). Formate also displayed a negative relationship with some elevated clinical markers in DPN. ROC curve analysis showed a good discriminative ability for formate in DPN with an area under the curve (AUC) value of 0.981. CONCLUSION: Formate could be considered a potential serum metabolic biomarker for DPN. The reduced level of formate in DPN may be associated with mitochondrial dysfunction and gut microbiota alteration. Monitoring the level of serum formate would be an important strategy for the early diagnosis of DPN and a supplement of formate may be a promising treatment for DPN in the future. Dove 2023-10-10 /pmc/articles/PMC10576463/ /pubmed/37842336 http://dx.doi.org/10.2147/DMSO.S428933 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Weisheng
Xue, Wangsheng
Zhou, Zeyu
Wang, Jiying
Qi, Hui
Sun, Shiyu
Jin, Tong
Yao, Ping
Zhao, Jian-Yuan
Lin, Fuqing
Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title_full Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title_fullStr Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title_full_unstemmed Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title_short Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
title_sort formate might be a novel potential serum metabolic biomarker for type 2 diabetic peripheral neuropathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576463/
https://www.ncbi.nlm.nih.gov/pubmed/37842336
http://dx.doi.org/10.2147/DMSO.S428933
work_keys_str_mv AT xuweisheng formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT xuewangsheng formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT zhouzeyu formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT wangjiying formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT qihui formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT sunshiyu formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT jintong formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT yaoping formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT zhaojianyuan formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy
AT linfuqing formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy